These results indicate that early ctDNA measurement may indicate treatment response, whereas ongoing monitoring of BRAF ctDNA levels could be a clinically useful marker for tumor response, similar to observations in EGFR-mutant NSCLC patients [184]. Here, BRAF is linked to non-small cell lung carcinoma.